Medtronic Raises FY2027 Revenue Guidance to 7.25%-7.75% Organic Growth and Adjusts EPS Outlook
Medtronic (NYSE:MDT) has raised its full-year fiscal year 2027 revenue guidance, projecting organic growth of between 7.25% and 7.75%. The company also updated its earnings per share (EPS) forecast to a range of $5.94-$6.00 for the period. In Q1 FY2027, Medtronic reported revenue of $9.8 billion and adjusted EPS of $1.45—both figures exceeded expectations according to CEO Geoffrey Martha. The strong performance marks an encouraging start to fiscal 2027.
Tickers: $MDT